Pfizer, Inc. (NYSE:PFE) initiated the shares trading at $31.18 and showed positive change of +0.29% while the stock’s final trade was registered at $ 31.42. However, its previous closing price was seen at $31.33. The stock negotiated total number of 21.27 million shares as compared to 3 months average volume of 23.96 million shares.
The stock price demonstrated downbeat change from its 50 day moving average of 32.11 and had been down from its 200 Day Moving Average of 34.16.
According to ZACKS data, different Brokerage Firms rated the PFE stock about their BUY, SELL or HOLD recommendations. Currently shares have been suggested as BUY from 0 brokerage firms and recommended as Strong Buy by 7 brokerage firms.0 brokerage firms have issued Sell rating for the company and Strong Sell rating was issued by 0 brokerage firms.9 brokerage firms have rated the company as a Hold. The Corporation has average brokerage recommendation (ABR) of 2.13 based on consensus of the brokerage firms issuing ratings.
The average true range of Pfizer Inc.’s (PFE) is recorded at 0.72 and the relative strength index of the stock stands 45.74. The stock price is going above to its 52 week low with 14.28% and lagging behind from its 52 week high with -14.42%. Analyst recommendation for this stock stands at 2.40. A look on the firm performance, its monthly performance is -1.69% and a quarterly performance of -8.73%. The stock price is trading downbeat from its 200 days moving average with -3.80% and down from 50 days moving average with -3.04%.
Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) climbed +2.49% and ended at $13.58 greater than previous closing price of $13.25. The total 618.23 thousand shares were bought and sold throughout the most recent trading session less than average volume of 994.79 thousand shares.
ITCI stock has received ratings from many brokerage firms according to ZACKS. Currently shares have been rated as Buy from 1 brokerage firms and 4 brokerage firms say as Strong Buy. 0 brokerage firms have suggested Sell for the company. 2 brokerage firms have recommended as a Hold. Strong Sell rating was given by 0 brokerage firms. The Company has average brokerage recommendation (ABR) of 1.71 based on consensus of the ZACKS brokerage firms.
Intra-Cellular Therapies, Inc.’s (ITCI) has price-to-cash ratio of 1.06 and price to sale ratio of 1906.63. A look on the firm performance, its monthly performance is 3.98% and a quarterly performance of -65.78%. The stock price is moving up from its 20 days moving average with 5.06% and isolated negatively from 50 days moving average with -31.78%.